Anticoagulation Therapy for Unprovoked Pulmonary Embolism

First-Line Alternatives to Apixaban

The American College of Cardiology recommends rivaroxaban as a suitable alternative to apixaban for patients with unprovoked pulmonary embolism, offering similar efficacy with once-daily dosing 1, 2
Rivaroxaban has the advantage of not requiring initial parenteral anticoagulation, making it more convenient for patients 3
The European Society of Cardiology suggests warfarin with a target INR of 2.0-3.0 as an effective and less expensive alternative if direct oral anticoagulants are unaffordable 2, 5

The American College of Chest Physicians recommends extended anticoagulation therapy beyond 3 months for patients with a first unprovoked pulmonary embolism and low or moderate bleeding risk 1, 5
For patients with a first unprovoked pulmonary embolism and high bleeding risk, 3 months of anticoagulation is recommended 5

The European Heart Journal recommends avoiding rivaroxaban and other direct oral anticoagulants in patients with creatinine clearance <30 mL/min 1
Patients with severe renal impairment may benefit from warfarin as the preferred option 3
The European Heart Journal suggests considering patient's age, comorbidities, concomitant medications, and history of bleeding when selecting an anticoagulant 1, 6

The American College of Chest Physicians recommends regular INR monitoring to maintain a target of 2.0-3.0 for warfarin 3, 5
All patients should be monitored for signs of bleeding or recurrent thrombosis regardless of anticoagulant choice 6